SHPMF (Shanghai Pharmaceuticals Holding Co) Moat Score: 5/10 (As of Jul. 01, 2026)


SHPMF Shanghai Pharmaceuticals Holding Co Ltd SHPMF
77 GF Score
Price $1.46
GF Value $1.89
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co Moat Score?

Shanghai Pharmaceuticals Holding Co SHPMF -4.58% 77 Moat Score is 5 as of Jul. 01, 2026. GuruFocus rates SHPMF with a GF Score™ of 77/100 and a GF Value™ of $1.89. The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, Shanghai Pharmaceuticals Holding Co ranks better than 92.44% on this metric.

Shanghai Pharmaceuticals Holding Co has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Shanghai Pharmaceuticals Holding Co has Narrow Moat: Shanghai Pharmaceuticals benefits from a solid market position in China and some regulatory advantages. However, it lacks strong global brand strength and significant network effects, resulting in a solid but not wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Shanghai Pharmaceuticals Holding Co might have Narrow Moat - Solid narrow moat.

Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Shanghai Pharmaceuticals Holding Co Moat Score Related Terms

SHPMF vs MCK, CAH, COR: Moat Score Comparison

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Pharmaceuticals Holding Co Moat Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Moat Score falls into.


SHPMF
77GF Score
Shanghai Pharmaceuticals Holding Co Ltd SHPMF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a Moat Score of 5 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #9 out of 119 companies in the Medical Distribution industry, placing it in the top 7.6%.
Is Shanghai Pharmaceuticals Holding Co's Moat Score too high?
Shanghai Pharmaceuticals Holding Co's current Moat Score is 5. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #9 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Moat Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #9 out of 119 companies for Moat Score. This places Shanghai Pharmaceuticals Holding Co in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Distribution company?
A good Moat Score depends on the Medical Distribution industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Shanghai Pharmaceuticals Holding Co's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current Moat Score of 5. The stock's GF Value™ is $1.89, compared to a current price of $1.46 — trading 22.8% below its estimated fair value. The current Moat Score is 5. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current Moat Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of $1.46 is trading 22.8% below its estimated GF Value™ of $1.89.

Key valuation signals for SHPMF:

  • Moat Score: 5
  • GF Value™: $1.89 vs. price of $1.46 (22.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Pharmaceuticals Holding Co Business Description

Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
77GF Score

Get the complete analysis for SHPMF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$1.89
GF Value